In conclusion, our result shows there has no serious side effect

In conclusion, our result shows there has no serious side effect of adenovirus MDR1 gene therapy in short term, which provide useful baseline data for future long-term studies aimed at evaluating the safety of Ad-EGFP-MDR1. Acknowledgements We thank present and former members of the surgery and oncology laboratory of advice and suggestions. We also thank Yong Chen and Qin Mou for their expert technical assistance. see more We thank Professor TongChuan He (Molecular Oncology Laboratory, the University of Chicago Medical Center) for providing labeled adenoviruses. This work was supported by grants from China National Natural Science Foundation (NO:30330590). Electronic supplementary material Additional file 1: Trypan

blue dye exclusion test. BMCs inviable were dyed by trypan blue. Every group of BMCs cultured was low viability losses, maintaining cell culture viability above 88%. A: BMCs with Ad-EGFP-MDR1. B: BMCs with PBS (DOC 1 MB) Additional file 2: Colon carcinoma detected by ultrasound. (A) The xenograft tumor in armpit was detected by ultrasound after 10 days of CT26 tumor cell injection. It was about 3 mm × 5 mm × 5 mm. (B) The blood vessel of the neoplasm. The speed of arterial blood was 0.017 m/s. (DOC 341 KB)

Additional file 3: Summary of immunobiology evaluations of adenovirus-specific antibody levels by ELISA. OD of group A and C had no significant difference with that of group B and D. Adenovirus-specific antibody did not increased at 3, 7, 14 days after transplatation in group A and C. (DOC 36 KB) Additional file 4: Torin 1 mouse SNF detected reversely with green fluorescent of HEK293. SNF on Day 3,7,14 after transplantation was detected by measuring the fluorescent intensity of HEK293 cells using a flow cytometry. SNF fantofarone against MLN2238 datasheet Ad-EGFP-MDR1 was not detected in all groups. (DOC 24 KB) Additional file 5: Tissue distribution

of Ad-EGFP-MDR1. The expression of P-gp by immunohistochemistry in group A on Day 14 after BMT. A to H, ×400. Samples were counterstained with hematoxylin, the brown staining indicating P-gp. In situ hybridization localized Human MDR1 expression in the tissues of group A Day 14 after BMT. A1 to H1, ×1000. MDR1 DNA was labeled with FITC (green signals). P-gp and MDR1 DNA expression could be detected in intestine (B), lung (C) and kidney (D), also in the BMCs (I), but they were not expressed in tumor (A), heart (E), liver (F), spleen (G) and brain (H). Human MDR1 still could be detected in BMCs of group A on Day 30 posttreatment. (DOC 4 MB) Additional file 6: Peripheral blood cell analyzed by hematology analyzer. In group A, C and D, WBC (A), RBC (B), Plt (C) and (Hb) (D) were decreased after 3 days of IBM-BMT. But only WBC in group C at that time had statistical significance compared with group D (P < 0.05). WBC and Plt in group A were increased after the tumor growth and at the end of first chemotherapy they were decreased with statistical significance (P < 0.05).

Comments are closed.